Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients-Reference-Cited by-同舟云学术

Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients

Published:2015-05-26 Issue:5 Volume:37 Page:865-872
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Quesada Pedro Rodríguez^ORCID,Esteban Laura López,García Jimena Ramón,Sánchez Rocío Vázquez,García Teresa Molina,Alonso-Vega Gabriel Gaspar,Ferrández Javier Sánchez-Rubio

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

http://link.springer.com/content/pdf/10.1007/s11096-015-0132-1.pdf

Reference48 articles.

1. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4(4):240–6.

2. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, et al. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011. J Korean Med Sci. 2013;28(1):67–73.

3. Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother. 2009;64(2):239–50.

4. Heath KV, Singer J, O’Shaughnessy MV, Montaner JSG, Hogg RS. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(2):211–7.

5. d’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antirretroviral therapy (HAART) regimen in a cohort of antirretroviral naïve patients. AIDS. 2000;14(5):499–507.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics of tenofovir drug transporters in the context of HBV: Is there an impact?;Biomedicine & Pharmacotherapy;2024-06

2. Prevalence and Risk Factors for Renal Insufficiency among Adults Living with HIV in Tanzania: Results from a Cross-Sectional Study in 2020–2021;Healthcare;2024-03-14

3. Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study;Infection & Chemotherapy;2023

4. Switch to DTG+3TC in a Highly Treatment-Experienced Person Living with HIV;Mediterranean Journal of Infection Microbes and Antimicrobials;2022-12-09

5. Serial changes in renal indices in chronic HCV patients with and without HIV co-infection receiving sofosbuvir and tenofovir-based therapies;Transactions of The Royal Society of Tropical Medicine and Hygiene;2022-11-18